{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:19:02Z","timestamp":1793132342778,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 della Svizzera italiana"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Doses delivered to the urethra have been associated with an increased risk to develop long-term urinary toxicity in patients undergoing stereotactic body radiotherapy (SBRT) for prostate cancer (PCa). Aim of the present systematic review is to report on the role of urethra-sparing SBRT (US-SBRT) techniques for prostate cancer, with a focus on outcome and urinary toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A systematic review of the literature was performed on the PubMed database on May 2023. Based on the urethra-sparing technique, 13 studies were selected for the analysis and classified in the two following categories: \u201curethra-steering\u201d SBRT (restriction of hotspots to the urethra) and \u201curethra dose-reduction\u201d SBRT (dose reduction to urethra below the prescribed dose).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>By limiting the urethra D<jats:sub>max<\/jats:sub> to 90GyEQD2 (\u03b1\/\u03b2\u2009=\u20093\u00a0Gy) with urethra-steering SBRT techniques, late genitourinary (GU) grade 2 toxicity remains mild, ranging between 12.1% and 14%. With dose-reduction strategies decreasing the urethral dose below 70 GyEQD2, the risk of late GU toxicity was further reduced (&lt;\u20098% at 5\u00a0years), while maintaining biochemical relapse-free survival rates up to 93% at 5\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>US-SBRT techniques limiting maximum doses to urethra below a 90Gy<jats:sub>EQD2<\/jats:sub> (\u03b1\/\u03b2\u2009=\u20093\u00a0Gy) threshold result in a low rate of acute and late grade\u2009\u2265\u20092 GU toxicity. A better understanding of clinical factors and anatomical substructures involved in the development of GU toxicity, as well as the development and use of adapted dose constraints, is expected to further reduce the long-term GU toxicity of prostate cancer patients treated with SBRT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-023-04579-6","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T10:02:48Z","timestamp":1693908168000},"page":"3287-3299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature"],"prefix":"10.1007","volume":"41","author":[{"given":"Jennifer","family":"Le Guevelou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Giovanni","family":"Bosetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Castronovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Angrisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"de Crevoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"4579_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer\u20142020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 79:243\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","journal-title":"Eur Urol"},{"key":"4579_CR2","unstructured":"NCCN Clinical Practice Guidelines in Oncology\u202f: Prostate Cancer. V 3.2022."},{"key":"4579_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/iju.14011","volume":"26","author":"K Hatano","year":"2019","unstructured":"Hatano K, Tohyama N, Kodama T et al (2019) Current status of intensity-modulated radiation therapy for prostate cancer: History, clinical results and future directions. Int J Urol Off J Jpn Urol Assoc 26:775\u2013784. https:\/\/doi.org\/10.1111\/iju.14011","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"4579_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clon.2012.05.002","volume":"24","author":"G Bauman","year":"2012","unstructured":"Bauman G, Rumble RB, Chen J et al (2012) Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol R Coll Radiol G B 24:461\u2013473. https:\/\/doi.org\/10.1016\/j.clon.2012.05.002","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"4579_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.canrad.2010.06.013","volume":"14","author":"I Latorzeff","year":"2010","unstructured":"Latorzeff I, Mazurier J, Boutry C et al (2010) Benefit of intensity modulated and image-guided radiotherapy in prostate cancer. Cancer Radiother J Soc Francaise Radiother Oncol 14:479\u2013487. https:\/\/doi.org\/10.1016\/j.canrad.2010.06.013","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol"},{"key":"4579_CR6","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, Hendry JH (2012) Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: \u03b1\/\u03b2 = 1.4 (0.9\u20132.2) Gy. Int J Radiat Oncol 82:e17\u2013e24. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.10.075","journal-title":"Int J Radiat Oncol"},{"key":"4579_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree AC, Ostler P, van der Voet H et al (2022) Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23:1308\u20131320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00517-4","journal-title":"Lancet Oncol"},{"key":"4579_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet 394:385\u2013395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6","journal-title":"The Lancet"},{"key":"4579_CR9","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","volume":"104","author":"WC Jackson","year":"2019","unstructured":"Jackson WC, Silva J, Hartman HE et al (2019) Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol 104:778\u2013789. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.051","journal-title":"Int J Radiat Oncol"},{"issue":"22","key":"4579_CR10","doi-asserted-by":"publisher","first-page":"03671","DOI":"10.1016\/j.ijrobp.2022.12.022","volume":"S0360\u20133016","author":"HR Lukka","year":"2022","unstructured":"Lukka HR, Deshmukh S, Bruner DW et al (2022) Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating 2 Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys S0360\u20133016(22):03671\u201303679. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.12.022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4579_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.clon.2021.12.006","volume":"34","author":"MT Corkum","year":"2022","unstructured":"Corkum MT, Achard V, Morton G, Zilli T (2022) Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go? Clin Oncol R Coll Radiol G B 34:340\u2013349. https:\/\/doi.org\/10.1016\/j.clon.2021.12.006","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"4579_CR12","doi-asserted-by":"publisher","unstructured":"Merrick GS, Butler WM, Wallner KE, et al (2006) Risk factors for the development of prostate brachytherapy related urethral strictures. J Urol 175:1376\u20131380; discussion 1381. https:\/\/doi.org\/10.1016\/S0022-5347(05)00681-6","DOI":"10.1016\/S0022-5347(05)00681-6"},{"key":"4579_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s0360-3016(01)01811-9","volume":"52","author":"GS Merrick","year":"2002","unstructured":"Merrick GS, Butler WM, Tollenaar BG et al (2002) The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 52:461\u2013468. https:\/\/doi.org\/10.1016\/s0360-3016(01)01811-9","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4579_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.brachy.2012.03.004","volume":"12","author":"BR Hindson","year":"2013","unstructured":"Hindson BR, Millar JL, Matheson B (2013) Urethral strictures following high-dose-rate brachytherapy for prostate cancer: Analysis of risk factors. Brachytherapy 12:50\u201355. https:\/\/doi.org\/10.1016\/j.brachy.2012.03.004","journal-title":"Brachytherapy"},{"key":"4579_CR15","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3389\/fonc.2020.00910","volume":"10","author":"V Panettieri","year":"2020","unstructured":"Panettieri V, Rancati T, Onjukka E et al (2020) External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. Front Oncol 10:910. https:\/\/doi.org\/10.3389\/fonc.2020.00910","journal-title":"Front Oncol"},{"key":"4579_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","volume":"112","author":"JE Leeman","year":"2022","unstructured":"Leeman JE, Chen Y-H, Catalano P et al (2022) Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. Int J Radiat Oncol Biol Phys 112:75\u201382. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.037","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4579_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijrobp.2022.01.022","volume":"113","author":"T Zilli","year":"2022","unstructured":"Zilli T, Achard V, Guevelou JL (2022) Intraprostatic Urethra: The New Kid on the Block for Prostate Cancer Radiation Therapy? Int J Radiat Oncol 113:92\u201395. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.01.022","journal-title":"Int J Radiat Oncol"},{"key":"4579_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","volume":"167","author":"VH Groen","year":"2022","unstructured":"Groen VH, van Schie M, Zuithoff NPA et al (2022) Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiother Oncol J Eur Soc Ther Radiol Oncol 167:127\u2013132. https:\/\/doi.org\/10.1016\/j.radonc.2021.12.027","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"4579_CR19","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman Dg (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009 Jul 2167e1000097","DOI":"10.1371\/journal.pmed.1000097"},{"key":"4579_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.adro.2018.09.007","volume":"4","author":"AM McDonald","year":"2019","unstructured":"McDonald AM, Dobelbower MC, Yang ES et al (2019) Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial. Adv Radiat Oncol 4:90\u201395. https:\/\/doi.org\/10.1016\/j.adro.2018.09.007","journal-title":"Adv Radiat Oncol"},{"key":"4579_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","volume":"147","author":"C Draulans","year":"2020","unstructured":"Draulans C, van der Heide UA, Haustermans K et al (2020) Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol 147:92\u201398. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.015","journal-title":"Radiother Oncol"},{"key":"4579_CR22","doi-asserted-by":"publisher","unstructured":"De Cock L, Draulans C, Pos FJ, et al (2023) From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol J Eur Soc Ther Radiol Oncol 109713. https:\/\/doi.org\/10.1016\/j.radonc.2023.109713","DOI":"10.1016\/j.radonc.2023.109713"},{"key":"4579_CR23","doi-asserted-by":"publisher","first-page":"20220803","DOI":"10.1259\/bjr.20220803","volume":"96","author":"M Cloitre","year":"2023","unstructured":"Cloitre M, Valerio M, Mampuya A et al (2023) Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I\/II study. Br J Radiol 96:20220803. https:\/\/doi.org\/10.1259\/bjr.20220803","journal-title":"Br J Radiol"},{"key":"4579_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijrobp.2018.09.023","volume":"103","author":"FG Herrera","year":"2019","unstructured":"Herrera FG, Valerio M, Berthold D et al (2019) 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a\/b Trial. Int J Radiat Oncol 103:320\u2013334. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.09.023","journal-title":"Int J Radiat Oncol"},{"key":"4579_CR25","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand DH, Tree AC, Ostler P et al (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20:1531\u20131543. https:\/\/doi.org\/10.1016\/S1470-2045(19)30569-8","journal-title":"Lancet Oncol"},{"key":"4579_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","volume":"9","author":"AU Kishan","year":"2023","unstructured":"Kishan AU, Ma TM, Lamb JM et al (2023) Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol 9:365\u2013373. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6558","journal-title":"JAMA Oncol"},{"key":"4579_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fonc.2019.00217","volume":"9","author":"D Pryor","year":"2019","unstructured":"Pryor D, Sidhom M, Arumugam S et al (2019) Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS). Front Oncol 9:217. https:\/\/doi.org\/10.3389\/fonc.2019.00217","journal-title":"Front Oncol"},{"key":"4579_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","volume":"1","author":"DB Fuller","year":"2018","unstructured":"Fuller DB, Falchook AD, Crabtree T et al (2018) Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes. Eur Urol Oncol 1:540\u2013547. https:\/\/doi.org\/10.1016\/j.euo.2018.06.013","journal-title":"Eur Urol Oncol"},{"key":"4579_CR29","doi-asserted-by":"publisher","unstructured":"Fuller DB, Crabtree T, Kane BL, et al (2022) High Dose \u201cHDR-Like\u201d Prostate SBRT: PSA 10-Year Results From a Mature, Multi-Institutional Clinical Trial. Front Oncol 12:935310. https:\/\/doi.org\/10.3389\/fonc.2022.935310","DOI":"10.3389\/fonc.2022.935310"},{"key":"4579_CR30","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","volume":"105","author":"AME Bruynzeel","year":"2019","unstructured":"Bruynzeel AME, Tetar SU, Oei SS et al (2019) A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. Int J Radiat Oncol 105:1086\u20131094. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.007","journal-title":"Int J Radiat Oncol"},{"issue":"23","key":"4579_CR31","doi-asserted-by":"publisher","first-page":"00301","DOI":"10.1016\/j.ijrobp.2023.03.057","volume":"S0360\u20133016","author":"T Zilli","year":"2023","unstructured":"Zilli T, Jorcano S, Bral S et al (2023) Every-Other-Day Versus Once-a-Week Urethra-Sparing Prostate Stereotactic Body Radiation Therapy: 5-Year Results of a Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys S0360\u20133016(23):00301\u201300302. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.03.057","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4579_CR32","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1002\/cam4.2966","volume":"9","author":"T Zilli","year":"2020","unstructured":"Zilli T, Jorcano S, Bral S et al (2020) Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results. Cancer Med 9:3097\u20133106. https:\/\/doi.org\/10.1002\/cam4.2966","journal-title":"Cancer Med"},{"key":"4579_CR33","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ijrobp.2020.06.002","volume":"108","author":"M Jaccard","year":"2020","unstructured":"Jaccard M, Zilli T, Dubouloz A et al (2020) Urethra-Sparing Stereotactic Body Radiation Therapy for Prostate Cancer: Quality Assurance of a Randomized Phase 2 Trial. Int J Radiat Oncol 108:1047\u20131054. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.06.002","journal-title":"Int J Radiat Oncol"},{"key":"4579_CR34","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2020.05.007","volume":"4","author":"SU Tetar","year":"2021","unstructured":"Tetar SU, Bruynzeel AME, Oei SS et al (2021) Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. Eur Urol Oncol 4:628\u2013634. https:\/\/doi.org\/10.1016\/j.euo.2020.05.007","journal-title":"Eur Urol Oncol"},{"key":"4579_CR35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/COC.0000000000000693","volume":"43","author":"S Parsai","year":"2020","unstructured":"Parsai S, Juloori A, Sedor G et al (2020) Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study. Am J Clin Oncol 43:469\u2013476. https:\/\/doi.org\/10.1097\/COC.0000000000000693","journal-title":"Am J Clin Oncol"},{"key":"4579_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijrobp.2021.03.027","volume":"111","author":"A Magli","year":"2021","unstructured":"Magli A, Farneti A, Faiella A et al (2021) Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer. Int J Radiat Oncol 111:93\u2013100. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.027","journal-title":"Int J Radiat Oncol"},{"key":"4579_CR37","doi-asserted-by":"publisher","unstructured":"Greco C, Pares O, Pimentel N, et al (2022) Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study. Front Oncol 12:863655. https:\/\/doi.org\/10.3389\/fonc.2022.863655","DOI":"10.3389\/fonc.2022.863655"},{"key":"4579_CR38","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","volume":"7","author":"C Greco","year":"2021","unstructured":"Greco C, Pares O, Pimentel N et al (2021) Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial. JAMA Oncol 7:700\u2013708. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0039","journal-title":"JAMA Oncol"},{"key":"4579_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.radonc.2019.07.018","volume":"139","author":"T Zilli","year":"2019","unstructured":"Zilli T, Franzese C, Bottero M et al (2019) Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. Radiother Oncol 139:83\u201386. https:\/\/doi.org\/10.1016\/j.radonc.2019.07.018","journal-title":"Radiother Oncol"},{"key":"4579_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.radonc.2020.12.013","volume":"156","author":"M Jaccard","year":"2021","unstructured":"Jaccard M, Ehrbar S, Miralbell R et al (2021) Single-fraction prostate stereotactic body radiotherapy: Dose reconstruction with electromagnetic intrafraction motion tracking. Radiother Oncol 156:145\u2013152. https:\/\/doi.org\/10.1016\/j.radonc.2020.12.013","journal-title":"Radiother Oncol"},{"key":"4579_CR41","doi-asserted-by":"crossref","unstructured":"Groen V Urethra and bladder dose-effect relations for genitourinary toxicity after EBRT for prostate cancer. ESTRO 2021 Abstr. Form","DOI":"10.1016\/S0167-8140(21)06937-1"},{"key":"4579_CR42","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/j.prro.2016.07.004","volume":"7","author":"L Zhang","year":"2017","unstructured":"Zhang L, Johnson J, Gottschalk AR et al (2017) Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol 7:e109\u2013e116. https:\/\/doi.org\/10.1016\/j.prro.2016.07.004","journal-title":"Pract Radiat Oncol"},{"key":"4579_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13014-018-1112-0","volume":"13","author":"T Zilli","year":"2018","unstructured":"Zilli T, Scorsetti M, Zwahlen D et al (2018) ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I\/II trial. Radiat Oncol 13:166. https:\/\/doi.org\/10.1186\/s13014-018-1112-0","journal-title":"Radiat Oncol"},{"key":"4579_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.radonc.2008.11.013","volume":"91","author":"L Sullivan","year":"2009","unstructured":"Sullivan L, Williams SG, Tai KH et al (2009) Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 91:232\u2013236. https:\/\/doi.org\/10.1016\/j.radonc.2008.11.013","journal-title":"Radiother Oncol"},{"key":"4579_CR45","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijrobp.2010.10.009","volume":"82","author":"N Mohammed","year":"2012","unstructured":"Mohammed N, Kestin L, Ghilezan M et al (2012) Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys 82:204\u2013212. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.10.009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4579_CR46","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.3389\/fonc.2020.01174","volume":"10","author":"M Marcello","year":"2020","unstructured":"Marcello M, Denham JW, Kennedy A et al (2020) Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials. Front Oncol 10:1174. https:\/\/doi.org\/10.3389\/fonc.2020.01174","journal-title":"Front Oncol"},{"key":"4579_CR47","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.ijrobp.2020.07.019","volume":"108","author":"E Mylona","year":"2020","unstructured":"Mylona E, Ebert M, Kennedy A et al (2020) Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population. Int J Radiat Oncol 108:1189\u20131195. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.07.019","journal-title":"Int J Radiat Oncol"},{"key":"4579_CR48","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.ejmp.2016.08.013","volume":"32","author":"I Improta","year":"2016","unstructured":"Improta I, Palorini F, Cozzarini C et al (2016) Bladder spatial-dose descriptors correlate with acute urinary toxicity after radiation therapy for prostate cancer. Phys Med 32:1681\u20131689. https:\/\/doi.org\/10.1016\/j.ejmp.2016.08.013","journal-title":"Phys Med"},{"key":"4579_CR49","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ijrobp.2013.10.042","volume":"88","author":"P Ghadjar","year":"2014","unstructured":"Ghadjar P, Zelefsky MJ, Spratt DE et al (2014) Impact of Dose to the Bladder Trigone on Long-Term Urinary Function After High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol 88:339\u2013344. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.10.042","journal-title":"Int J Radiat Oncol"},{"key":"4579_CR50","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fonc.2020.00555","volume":"10","author":"A Pepin","year":"2020","unstructured":"Pepin A, Aghdam N, Shah S et al (2020) Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP). Front Oncol 10:555. https:\/\/doi.org\/10.3389\/fonc.2020.00555","journal-title":"Front Oncol"},{"key":"4579_CR51","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.1016\/j.clon.2022.05.021","volume":"34","author":"C Huck","year":"2022","unstructured":"Huck C, Achard V, Zilli T (2022) Surgical Treatments of Benign Prostatic Hyperplasia and Prostate Cancer Stereotactic Radiotherapy: Impact on Long-Term Genitourinary Toxicity. Clin Oncol R Coll Radiol G B 34:e392\u2013e399. https:\/\/doi.org\/10.1016\/j.clon.2022.05.021","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"4579_CR52","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/j.prro.2015.02.001","volume":"5","author":"ZA Seymour","year":"2015","unstructured":"Seymour ZA, Chang AJ, Zhang L et al (2015) Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol 5:e465\u2013e472. https:\/\/doi.org\/10.1016\/j.prro.2015.02.001","journal-title":"Pract Radiat Oncol"},{"key":"4579_CR53","doi-asserted-by":"publisher","unstructured":"Katz AJ, Kang J (2014) Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study. Front Oncol 4:. https:\/\/doi.org\/10.3389\/fonc.2014.00301","DOI":"10.3389\/fonc.2014.00301"},{"key":"4579_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13014-014-0241-3","volume":"9","author":"E Janowski","year":"2014","unstructured":"Janowski E, Chen LN, Kim JS et al (2014) Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (\u226550 cm3). Radiat Oncol 9:241. https:\/\/doi.org\/10.1186\/s13014-014-0241-3","journal-title":"Radiat Oncol"},{"key":"4579_CR55","doi-asserted-by":"publisher","unstructured":"Haas JA, Mendez C, Witten MR, et al (2021) Stereotactic Body Radiation Therapy for Ultra-Large (> 100 cc) Prostate Glands: Oncologic, Toxicity and Patient-Reported Outcomes. Int J Radiat Oncol 111:e276. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.892","DOI":"10.1016\/j.ijrobp.2021.07.892"},{"key":"4579_CR56","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1748-717X-7-82","volume":"7","author":"J Vainshtein","year":"2012","unstructured":"Vainshtein J, Abu-Isa E, Olson KB et al (2012) Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy. Radiat Oncol 7:82. https:\/\/doi.org\/10.1186\/1748-717X-7-82","journal-title":"Radiat Oncol"},{"key":"4579_CR57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","volume":"109","author":"CR King","year":"2013","unstructured":"King CR, Freeman D, Kaplan I et al (2013) Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 109:217\u2013221. https:\/\/doi.org\/10.1016\/j.radonc.2013.08.030","journal-title":"Radiother Oncol"},{"key":"4579_CR58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.radonc.2004.09.004","volume":"74","author":"G Kov\u00e1cs","year":"2005","unstructured":"Kov\u00e1cs G, P\u00f6tter R, Loch T et al (2005) GEC\/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol 74:137\u2013148. https:\/\/doi.org\/10.1016\/j.radonc.2004.09.004","journal-title":"Radiother Oncol"},{"key":"4579_CR59","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13014-019-1424-8","volume":"14","author":"Y Dekura","year":"2019","unstructured":"Dekura Y, Nishioka K, Hashimoto T et al (2019) The urethral position may shift due to urethral catheter placement in the treatment planning for prostate radiation therapy. Radiat Oncol 14:226. https:\/\/doi.org\/10.1186\/s13014-019-1424-8","journal-title":"Radiat Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04579-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T09:07:51Z","timestamp":1699434471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04579-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["4579"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04579-6","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"7 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No competing interests concerning the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest:"}}]}}